Expanding Antiretroviral Options in Resource-Limited Settings-A Cost-Effectiveness Analysis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2009-09-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1097/QAI.0b013e3181a4f9c4PMID 19448557PMCID PMC2757100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009

  2009cited by this paper
• Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)

  2008cited by this paper
• Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

  2008cited by this paper
• Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.

  2008cited by this paper
• The challenge of HIV-1 subtype diversity.

  2008cited by this paper
• Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting

  2008cited by this paper
• Initiating Rather than Deferring Haart at a CD4+ Count Between 351-500 Cells/mm 3 is Associated with Improved Survival

  2008cited by this paper
• Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania.

  2007cited by this paper
• Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

  2007cited by this paper
• Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda

  2007cited by this paper
• The cost effectiveness of antiretroviral treatment strategies in resource-limited settings

  2007cited by this paper
• HIV viral load monitoring in resource-limited regions: optional or necessary?

  2007cited by this paper
• Comparative Costs of Inpatient Care for HIV-Infected and Uninfected Children and Adults in Soweto, South Africa

  2007cited by this paper
• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

  2007influential reference
• Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

  2007influential reference
• Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

  2007cited by this paper
• A wake-up call for global access to salvage HIV drug regimens.

  2007cited by this paper
• The Role of Adherence to Antiretroviral Therapy in the Management of HIV Infection

  2007cited by this paper
• Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited

  2007cited by this paper
• HIV-1 viral load testing cost in developing countries: what’s new?

  2007cited by this paper
• Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

  2007influential reference
• Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting

  2006cited by this paper
• When to Initiate Highly Active Antiretroviral Therapy in Sub-Saharan Africa? A South African Cost-Effectiveness Study

  2006cited by this paper
• Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study.

  2006cited by this paper
• Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients

  2006cited by this paper
• Cost Effectiveness and Resource Allocation Open Access the Association between Diabetes Related Medical Costs and Glycemic Control: a Retrospective Analysis

  2006cited by this paper
• Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

  2006cited by this paper
• The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa – a primary data analysis

  2006cited by this paper
• CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa: Implications for Prophylaxis and Treatment

  2006cited by this paper
• Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.

  2006cited by this paper
• Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

  2006cited by this paper
• Academic Editor: Andrew Carr, St.

  2005cited by this paper
• Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

  2005influential reference
• Evaluation of Two Commercially Available, Inexpensive Alternative Assays Used for Assessing Viral Load in a Cohort of Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients from South Africa

  2005cited by this paper
• Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach

  2005cited by this paper
• Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

  2005cited by this paper
• Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection

  2004cited by this paper
• Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

  2004influential reference
• Joint United Nations Programme on HIV/AIDS.

  2004cited by this paper
• Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

  2004cited by this paper
• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

  2003cited by this paper
• Adherence is not a barrier to successful antiretroviral therapy in South Africa

  2003cited by this paper
• Macroeconomics and health: investing in health for economic development

  2002cited by this paper
• Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

  2002cited by this paper
• Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

  2001cited by this paper
• Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

  2001cited by this paper
• The costs and perceived quality of care for people living with HIV / AIDS in the Western Cape Province in South Africa.

  2000cited by this paper
• Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.

  1998cited by this paper
• Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection

  1997cited by this paper

• Global Estimates for the Lifetime Cost of Managing HIV: A Systematic Review

  2020cites this paper
• Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa

  2019cites this paper
• Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level.

  2018cites this paper
• Mortality along the continuum of HIV care in Rwanda: a model-based analysis

  2016cites this paper
• Challenges in the integration of TB and HIV care : evidence for improving patient management and health care policy.

  2016cites this paper
• Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa

  2015cites this paper
• Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy.

  2014cites this paper
• Fifteen million people on antiretroviral treatment by 2015: treatment as prevention

  2013cites this paper
• Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

  2012cites this paper
• The State of Health Economic Research in South Africa

  2012cites this paper
• Affordability, cost and cost-effectiveness of universal anti-retroviral therapy for HIV

  2012cites this paper
• The Cost-Effectiveness of Cotrimoxazole in People With Advanced HIV Infection Initiating Antiretroviral Therapy in Sub-Saharan Africa

  2012cites this paper
• La mégère apprivoisée : élaborer des stratégies pour la gestion de la résistance aux médicaments dans la grippe et l'infection par le virus de l'immunodéficience humaine

  2012cites this paper
• Utilisation du modèle CEPAC en appui à la recherche clinique dans le domaine de la prise en charge des adultes infectés par le VIH en Afrique sub-saharienne

  2012cites this paper
• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis

  2011cites this paper
• Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

  2010cites this paper
• Economic evaluation of ART in resource-limited countries

  2010cites this paper
• Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting

  2010cites this paper
• Comparative effectiveness of HIV testing and treatment in highly endemic regions.

  2010cites this paper
• The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States

  2010cites this paper